These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

62 related articles for article (PubMed ID: 7111306)

  • 1. Mechanisms of platelet aggregation by human tumor cell lines.
    Jamieson GA; Bastida E; Ordinas A
    Prog Clin Biol Res; 1982; 89():405-13. PubMed ID: 7111306
    [No Abstract]   [Full Text] [Related]  

  • 2. Positive and negative aggregation responses to cultured human tumor cell lines among different normal individuals.
    Bastida E; Ordinas A; Jamieson GA
    Prog Clin Biol Res; 1982; 89():225-31. PubMed ID: 7111299
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differentiation of platelet-aggregating effects of human tumor cell lines based on inhibition studies with apyrase, hirudin, and phospholipase.
    Bastida E; Ordinas A; Giardina SL; Jamieson GA
    Cancer Res; 1982 Nov; 42(11):4348-52. PubMed ID: 6290033
    [No Abstract]   [Full Text] [Related]  

  • 4. Interaction of platelets and tumor cells.
    Steiner M
    Prog Clin Biol Res; 1982; 89():383-403. PubMed ID: 7111305
    [No Abstract]   [Full Text] [Related]  

  • 5. Inhibition of the platelet-aggregating activity of two human adenocarcinomas of the colon and an anaplastic murine tumor with a specific thrombin inhibitor: dansylarginine N-(3-ethyl-1, 5-pentanediyl)amide.
    Pearlstein E; Ambrogio C; Gasic G; Karpatkin S
    Prog Clin Biol Res; 1982; 89():479-502. PubMed ID: 6287488
    [No Abstract]   [Full Text] [Related]  

  • 6. Role of platelet membrane glycoproteins Ib/IX and IIb/IIIa, and of platelet alpha-granule proteins in platelet aggregation induced by human osteosarcoma cells.
    Clezardin P; Drouin J; Morel-Kopp MC; Hanss M; Kehrel B; Serre CM; Kaplan C; Delmas PD
    Cancer Res; 1993 Oct; 53(19):4695-700. PubMed ID: 7691402
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Idiosyncratic platelet responses to human tumour cells.
    Bastida E; Ordinas A; Jamieson GA
    Nature; 1981 Jun; 291(5817):661-2. PubMed ID: 6264316
    [No Abstract]   [Full Text] [Related]  

  • 8. Differential regulation of platelet aggregation by matrix metalloproteinases-9 and -2.
    Fernandez-Patron C; Martinez-Cuesta MA; Salas E; Sawicki G; Wozniak M; Radomski MW; Davidge ST
    Thromb Haemost; 1999 Dec; 82(6):1730-5. PubMed ID: 10613662
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Platelet cancer cell interaction in metastasis formation. Platelet aggregation inhibitors: a possible approach to metastasis prevention.
    Gastpar H; Ambrus JL; Ambrus CM
    Prog Clin Biol Res; 1982; 89():63-82. PubMed ID: 7111310
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma membrane vesicles as mediators of interactions between tumor cells and components of the hemostatic and immune systems.
    Gasic GJ; Gasic TB
    Prog Clin Biol Res; 1982; 89():429-44. PubMed ID: 7111308
    [No Abstract]   [Full Text] [Related]  

  • 11. A stable leukocyte-derived factor inhibits platelet aggregation.
    Liu JJ; Xie B; Smith IL; Johnston CI; Buxton BF
    Biochem Biophys Res Commun; 1994 Jun; 201(2):878-82. PubMed ID: 8003026
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Platelet aggregation inhibitors and metastatic spread of neoplastic cells.
    Ambrus JL; Ambrus CM; Gastpar H
    Prog Clin Biol Res; 1982; 89():83-95. PubMed ID: 7111311
    [No Abstract]   [Full Text] [Related]  

  • 13. Platelet aggregation-induced by caco-2 cells: regulation by matrix metalloproteinase-2 and adenosine diphosphate.
    Medina C; Jurasz P; Santos-Martinez MJ; Jeong SS; Mitsky T; Chen R; Radomski MW
    J Pharmacol Exp Ther; 2006 May; 317(2):739-45. PubMed ID: 16424148
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bromelain proteases reduce human platelet aggregation in vitro, adhesion to bovine endothelial cells and thrombus formation in rat vessels in vivo.
    Metzig C; Grabowska E; Eckert K; Rehse K; Maurer HR
    In Vivo; 1999; 13(1):7-12. PubMed ID: 10218125
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanisms underlying increased platelet reactivity in patients with peripheral arterial disease. Preliminary results.
    Reininger CB; Boeger CA; Steckmeier B; Spannagl M; Scweiberer L
    Int Angiol; 1999 Jun; 18(2):163-70. PubMed ID: 10424375
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Animal models for the study of platelet-tumor cell interactions.
    Donati MB; Rotillio D; Delaini F; Giavazzi R; Mantovani A; Poggi A
    Prog Clin Biol Res; 1982; 89():159-76. PubMed ID: 7202205
    [No Abstract]   [Full Text] [Related]  

  • 17. Studies on fibronectin and its domains. I. Novel recombinant cell-binding domain of fibronectin--a modulator of human platelet functions.
    Vogel T; Werber MM; Guy R; Levanon A; Nimrod A; Legrand C; Gorecki M; Eldor A; Panet A
    Arch Biochem Biophys; 1993 Jan; 300(1):501-9. PubMed ID: 8424687
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of the platelet-aggregating activity of tumor cells.
    Hara Y; Steiner M; Baldini MG
    Cancer Res; 1980 Apr; 40(4):1217-22. PubMed ID: 7357551
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular mechanisms of fibrin gel clot retraction by platelets and cultured tumor cells.
    Tanoue K; Katagiri Y; Suzuki H
    Pol J Pharmacol; 1996; 48(3):341-3. PubMed ID: 9112674
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel strategy for generating platelet-like fragments from megakaryocytic cell lines and human progenitor cells.
    Gandhi MJ; Drachman JG; Reems JA; Thorning D; Lannutti BJ
    Blood Cells Mol Dis; 2005; 35(1):70-3. PubMed ID: 15923131
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.